NCT00893594

Efficacy of Sumatriptan With Naprosyn in Migraine With Aura

A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Dent Neurologic Institute · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This is a double-blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.

Conditions

• Migraine With Aura

Interventions

Type	Name	Description
DRUG	sumatriptan with naprosyn	Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
DRUG	placebo	Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.

Timeline

• Start date: 2010-10-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2009-05-06
• Last updated: 2015-02-19

Locations

1 site across 1 country: United States